- Moody's•5 days ago
Horizon Pharma, Inc. -- Moody's affirms Horizon Pharma at B2, raises SGL rating to SGL-1; stable outlook
Rating Action: Moody's affirms Horizon Pharma at B2, raises SGL rating to SGL-1; stable outlook. Global Credit Research- 22 Mar 2017. New York, March 22, 2017-- Moody's Investors Service affirmed certain ...
- GlobeNewswire•6 days ago
Horizon Pharma plc to Present Data on RAVICTI® (glycerol phenylbutyrate) Oral Liquid for Urea Cycle Disorder Patients Aged Two Months to Two Years
DUBLIN, Ireland, March 22, 2017-- Horizon Pharma plc, a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible ...
- Zacks•11 days ago
Horizon Pharma (HZNP) can Be a Great Stock for Value Investors on the back of its strong key value statistics.
HZNP : Summary for Horizon Pharma plc - Yahoo Finance
Horizon Pharma Public Limited Company (HZNP)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||11.14 x 100|
|Ask||16.50 x 100|
|Day's Range||14.20 - 14.87|
|52 Week Range||13.05 - 23.44|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-14.27|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|